Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70288 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Guanyu Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vertex Pharmaceuticals Incorporated, Boston, MA, USA. Hauptthemen laut MEDLINE: Pyridones, Pyrazoles, Rivaroxaban, Models, Biological. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vertex Pharmaceuticals.
Abstract (Originalsprache)
Suzetrigine (VX‐548) is a first‐in‐class, oral, non‐opioid, FDA‐approved analgesic for the treatment of moderate to severe acute pain. Based on Phase 1 clinical drug–drug interaction (DDI) studies, suzetrigine is a weak‐to‐moderate cytochrome P450 3A (CYP3A) inducer and thus has the potential to decrease exposure and impact efficacy of CYP3A substrates, such as apixaban and rivaroxaban, which are commonly used as anticoagulants peri‐ and post‐operatively. Given this, it is important to assess the DDIs of apixaban and rivaroxaban with suzetrigine. Physiologically based pharmacokinetic (PBPK) models are commonly used to assess DDIs mediated through modulation of CYP3A and were used here to quantify the potential effect of co‐administration of suzetrigine on apixaban and rivaroxaban PK. The PBPK models were validated using observed data from suzetrigine, apixaban, and rivaroxaban clinical DDI studies. The validated models predict that suzetrigine decreases apixaban AUCinf by 6.1% (90% confidence interval [CI]: 5.7% to 6.4%) and Cmax by 1.8% (90% CI: 1.7% to 1.9%), and rivaroxaban AUCinf by 8.4% (90% CI: 7.2% to 9.6%) and Cmax by 3.5% (90% CI: 3.3% to 3.7%). The predicted small reductions in apixaban and rivaroxaban exposures (AUCinf
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
- Vertex Pharmaceuticals Incorporated, San Diego, CA, USA.
ORCID-Profile: Guanyu Wang, Elizabeth Lakota, Bo Feng, Brian Hare
Förderung
- Vertex Pharmaceuticals
Zitieren
APA
Wang, G., Lakota, E., Feng, B., Jiang, L., Liang, G., & Hare, B. (2026). Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70288
Vancouver
Wang G, Lakota E, Feng B, Jiang L, Liang G, Hare B. Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70288
BibTeX
@article{Wang2026,
author = {Wang, Guanyu and Lakota, Elizabeth and Feng, Bo and Jiang, Licong and Liang, Guiqing and Hare, Brian},
title = {Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70288}
}
EUVIMED